ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NIH trial to add Trevena’s TRV027 for Covid-19 treatment pharmaceutical-technology
May 08, 2021TRV027 is an angiotensin II receptor type 1 (AT1 receptor) selective agonist and fights disruption within the renin-angiotensin-aldosterone system (RAAS) by attaching to and rebalancing AT1 receptor activation.
Pharma Sources Insight January 2025
